Zobrazeno 1 - 3
of 3
pro vyhledávání: '"37"'
Autor:
Wondwosen Ergetie, Matthew A. Cohen, Anjali Saqi, Dawit Kebede Huluka, Aschalew Worku, Helen Fernandes, Deborah A. Haisch, Lillian M. Zerihun, Pierre P. Massion, Amsalu Bekele Binegdie, Neil W. Schluger, Tewodros Haile Gebremariam, Mathewos A. Woldegeorgis, Charles B. Sherman
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100196-(2021)
JTO Clinical and Research Reports
JTO Clinical and Research Reports
Introduction Lung cancer is the most common cause of cancer deaths worldwide, accounting for 1.8 million deaths each year. Only 20% of lung cancer cases are reported to occur in low- and middle-income countries. An estimated 1.5% of all Ethiopian can
Autor:
Shulin Liu, Wenfeng Fang, Xin Li, Benyuan Jiang, Zhonghan Zhang, Jingyi Zhao, Yunpeng Yang, Hongyun Zhao, Yang Wei
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100193-(2021)
Introduction EGFR G724S has been described to mediate resistance to first- and third-generation EGFR tyrosine kinase inhibitors (TKIs). In vitro experiments have provided compelling evidence that G724S retains sensitivity for afatinib. Nevertheless,
Autor:
M. Hardy-Werbin, Álvaro Taus, Didac Ramal, Alex Corbera, Pedro Rocha, Enric Ripoll, Mayra Orrillo, Edurne Arriola, L. Moliner, Joan Gibert, David Casadevall, Júlia Perera-Bel, Flavio Zuccarino
Publikováno v:
JTO Clinical and Research Reports
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100115-(2021)
JTO Clinical and Research Reports, Vol 2, Iss 1, Pp 100115-(2021)
Introduction Hyperprogressive disease (HPD) as a consequence of immune checkpoint inhibitors in NSCLC has been reported in multiple studies. However, inconsistent results in incidence and survival outcomes within studies, together with different asse